School of Medicine
Showing 11-20 of 61 Results
Clinical Associate Professor, Medicine - Infectious Diseases
Current Research and Scholarly Interests Completed a Masters degree in Health Services Research in 2012. Research focused on using network models to develop a clinical research agenda for neglected tropical diseases.
Clinical Assistant Professor, Medicine - Vaden Health Center
Current Research and Scholarly Interests At Stanford University School of Medicine, one of our major goals is to translate research insights into practical advances that enhance and prolong life. We foster a two-way transfer of knowledge between research laboratories and patient-care settings. Our faculty, staff, postdoctoral scholars and students engage in interdisciplinary efforts to turn this knowledge into therapies that treat or prevent disease.
Clinical Assistant Professor, Medicine - Immunology & Rheumatology
Bio Tamiko Katsumoto, MD, is a Clinical Assistant Professor in the Division of Immunology and Rheumatology at Stanford University. She earned her MD from the University of California, San Francisco. She completed her internal medicine residency and rheumatology fellowship at UCSF, including a postdoc in the immunology lab of Dr. Arthur Weiss. Dr. Katsumoto?s research interests include the discovery of novel biomarkers to predict the development of immune-related adverse events in cancer patients on immune checkpoint inhibitor therapies, and optimizing the management of such complications. She is fascinated by the relationship between cancer and autoimmune diseases such as scleroderma and dermatomyositis, the paraneoplastic manifestations of various cancers, and the rheumatic complications of graft vs. host disease. She has spent time at Genentech, where she led several clinical trials in immunology. She also serves as a grant reviewer for the American College of Rheumatology Translational/Clinical Study Section and serves on the Medical and Scientific Board of the Northern California Chapter of the Arthritis Foundation.
Professor (Research) of Medicine (Infectious Diseases and Geographic Medicine), Emeritus
Current Research and Scholarly Interests Treatment and evaluation of HIV infectionin the United States and Europe through the AIDS Clinical Trials Group (ACTG). International HIV pathogenesis work includes studies in Zimbabwe, South Africa, and India where we are particularly interested in the pandemic of subtype C HIV-1, TB and other co-infections. The lab currently is focused on drug resistance, envelope tropism and the pathogenesis of HIV.
Professor of Neurosurgery and of Medicine (Endocrinology) at the Stanford University Medical Center, Lucile Salter Packard Children's Hospital and at the Palo Alto Veterans Affairs Health Care System
Current Research and Scholarly Interests Dr. Katznelson is an internationally known neuroendocrinologist and clinical researcher, with research expertise in the diagnosis and management of hypopituitarism, the effects of hormones on neurocognitive function, and the development of therapeutics for acromegaly and Cushingĺs syndrome, and neuroendocrine tumors. Dr. Katznelson is the medical director of the multidisciplinary Stanford Pituitary Center, a program geared for patient management, clinical research and patient education
Instructor, Medicine - Cardiovascular Medicine
Bio Dr. Kawana joined Advanced Heart Failure and Transplant Cardiology group in 2018 as an Instructor in the Division of Cardiovascular Medicine. He completed his internal medicine, cardiovascular medicine and heart failure training at Stanford. He also completed postdoctoral research fellowship under Dr. James Spudich in Department of Biochemistry. He sees advanced heart failure patients in clinic, and attends on inpatient service taking care of post-heart transplant patients and patients on MCS support. His research interests are in the fundamental mechanism of inherited cardiomyopathies, and he studies the effect of gene mutation on the cardiac sarcomere function using cutting-edge biochemical and biophysical approach, which would lead to development of novel pharmacotherapy that directly modulates cardiac muscle protein.